Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 23, 2026 07:00 ET | Source: AAVantgarde

AAVantgarde to Participate in ARVO 2026, with Presentations at Key Pre-events and New Clinical Data from the LUCE Phase 1/2 Study

MILAN, April 23, 2026 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering next-generation gene therapies for inherited retinal diseases (IRDs) has...
April 23, 2026 07:00 ET | Source: Jade Biosciences

Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO and VANCOUVER, British Columbia, April 23, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on...
April 23, 2026 07:00 ET | Source: Antag Therapeutics

Antag Therapeutics to present data on AT7687, its first-in-class GIPR antagonist peptide at the American Diabetes Association’s 2026 Scientific Sessions

Copenhagen, Denmark, 23 April 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today announces that it will...
April 23, 2026 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026

WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
April 23, 2026 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026

STAFFORD, Texas, April 23, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
April 23, 2026 04:00 ET | Source: Epitopea

Epitopea Announces Approval of OVACT Clinical Trial Application for CryptiVax-1001 in Advanced High-Grade Serous Ovarian Cancer

CAMBRIDGE, United Kingdom and MONTREAL, April 23, 2026 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic biotech developing off-the-shelf, durable, RNA-based cancer immunotherapies, today announced that...
April 23, 2026 04:00 ET | Source: ENA Respiratory

ENA Respiratory Appoints Melissa Faris to Board

MELBOURNE, Australia, April 23, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of symptomatic...
April 23, 2026 03:00 ET | Source: PulseSight Therapeutics S.A.S

Last patient, last visit completed in Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA)

-Results to be presented at ARVO 2026 Annual Meeting- PARIS, April 23, 2026 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive...
April 23, 2026 01:30 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting

OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting
April 23, 2026 01:00 ET | Source: Santhera Pharmaceuticals Holding AG

Santhera Appoints Orlando Oliveira as Chief Executive Officer

Ad hoc announcement pursuant to Art. 53 LR. Dario Eklund to hand over leadership following planned transition Pratteln, Switzerland, April 23, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces...